VistaGen Therapeutics (VTGN)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	62.79 mm	62.79 mm	62.79 mm	62.79 mm	62.79 mm	62.79 mm
Cash burn (monthly)	(no burn)	1.79 mm	6.68 mm	5.46 mm	4.59 mm	4.41 mm
Cash used (since last report)	n/a	4.51 mm	16.84 mm	13.74 mm	11.55 mm	11.12 mm
Cash remaining	n/a	58.28 mm	45.95 mm	49.04 mm	51.23 mm	51.67 mm
Runway (months of cash)	n/a	32.6	6.9	9.0	11.2	11.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

VTGN institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	61	40	+52.5%
Opened positions	24	7	+242.9%
Closed positions	3	14	-78.6%
Increased positions	16	6	+166.7%
Reduced positions	9	10	-10.0%

13F shares	Current	Prev Q	Change
Total value	44.93 bn	26.16 bn	+71.7%
Total shares	64.31 mm	55.33 mm	+16.2%
Total puts	548.60 k	190.00 k	+188.7%
Total calls	107.10 k	0.00	NEW
Total put/call ratio	5.1	Infinity	NaN%

Largest owners	Shares	Value	Change
Venrock Healthcare Capital Partners II	20.70 mm	$26.49 mm	0.0%
Growth Equity Opportunities 17	16.30 mm	$35.05 mm	0.0%
Lincoln Park Capital Fund	4.61 mm	$3.68 mm	0.0%
Biotechnology Value Fund L P	3.08 mm	$9.07 mm	+11.1%
TCG Crossover Management	2.68 mm	$7.90 bn	0.0%
StemPoint Capital	2.33 mm	$5.95 bn	+26.1%
Great Point Partners	2.06 mm	$6.04 mm	+205.0%
TCG Crossover GP II	2.03 mm	$6.97 mm	0.0%
Vanguard	2.02 mm	$5.96 bn	+12.7%
Nantahala Capital Management	1.98 mm	$5.85 bn	NEW

Largest transactions	Shares	Bought/sold	Change
Nantahala Capital Management	1.98 mm	+1.98 mm	NEW
Commodore Capital	1.58 mm	+1.58 mm	NEW
Great Point Partners	2.06 mm	+1.38 mm	+205.0%
Sphera Funds Management	808.55 k	+808.55 k	NEW
JPM JPMorgan Chase & Co.	772.24 k	+772.23 k	+4826425.0%
StemPoint Capital	2.33 mm	+481.70 k	+26.1%
Diadema Partners	442.52 k	+442.52 k	NEW
Biotechnology Value Fund L P	3.08 mm	+307.08 k	+11.1%
Almitas Capital	254.66 k	+254.66 k	NEW
Vanguard	2.02 mm	+227.19 k	+12.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VTGN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Dec 25	Nick B. Tressler	Common Stock Common Stock	Grant	Acquire A	No	No	4.43	150,000	664.50 k	150,000
27 Oct 25	Paul R Edick	Stock Option Common Stock	Grant	Acquire A	No	No	3.9	35,200	137.28 k	35,200
9 Sep 25	Cunningham Ann Michelle	NQSO Common Stock	Grant	Acquire A	No	No	3.61	17,600	63.54 k	17,600

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Vistagen Presents Data Showing PH80's Potential As Rapid Intranasal Treatment For Menopause Hot Flashes, At The Menopause Society 2025 Annual Meeting

26 Nov 25

Research supports the product candidate's non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkersVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with

12 Health Care Stocks Moving In Monday's After-Market Session

17 Nov 25

VistaGen Therapeutics Q2 EPS $(0.54) Misses $(0.48) Estimate, Sales $258.000K Beat $243.333K Estimate

13 Nov 25

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 13.45 percent. This is a 28.57 percent decrease over losses of $(0.42) per

Earnings Scheduled For November 13, 2025

13 Nov 25

Examining the Future: VistaGen Therapeutics's Earnings Outlook

12 Nov 25